Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2015

01.10.2015 | Short Research Report

Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?

verfasst von: Ho Choi, JiHyeon Ryu, Heenam Seo, MinKu Kang, Eunyoung Kim

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background A double maintenance dose of clopidogrel at 150 mg daily has been suggested as an effective alternative treatment for patients who have clopidogrel resistance. Objective To determine if a double maintenance dose of clopidogrel can overcome the low drug response rate observed in patients who have clopidogrel resistance while on a 75 mg daily standard maintenance dose of clopidogrel. Methods A retrospective analysis was conducted in South Korean patients who underwent a platelet function test and received a double maintenance dose of clopidogrel at a secondary medical institution between January 2011 and June 2012. The primary endpoint was to assess clopidogrel response using an adenosine diphosphate test after a double maintenance dose of clopidogrel. The secondary endpoint was the presence of factors that could affect response to clopidogrel. Results Of 389 patients identified, 77 patients were eligible for this study. Values from the adenosine diphosphate test decreased significantly in 63 patients (82 %) after a double maintenance dose of clopidogrel (p < 0.001). A total of 37 patients (48 %) overcame clopidogrel resistance. Concurrent disease appeared to be a contributory factor in clopidogrel resistance. Conclusion A double maintenance dose of clopidogrel at 150 mg daily was associated with a reduction in adenosine diphosphate-induced platelet aggregation in South Korean patients who previously exhibited clopidogrel resistance.
Literatur
1.
Zurück zum Zitat Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003;3:113–22.CrossRefPubMed Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003;3:113–22.CrossRefPubMed
2.
Zurück zum Zitat O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425.CrossRefPubMed O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425.CrossRefPubMed
3.
Zurück zum Zitat Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.CrossRefPubMed Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.CrossRefPubMed
4.
Zurück zum Zitat De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008;100:196–203.PubMed De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008;100:196–203.PubMed
5.
Zurück zum Zitat Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost. 2010;103:841–8.CrossRefPubMed Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost. 2010;103:841–8.CrossRefPubMed
6.
Zurück zum Zitat Tavassoli N, Voisin S, Carrie D, Lapeyre MM, Galinier M, Montastruc JL. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs. 2010;10:29–35.CrossRefPubMed Tavassoli N, Voisin S, Carrie D, Lapeyre MM, Galinier M, Montastruc JL. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs. 2010;10:29–35.CrossRefPubMed
7.
Zurück zum Zitat Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–105.CrossRefPubMed Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–105.CrossRefPubMed
8.
Zurück zum Zitat Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–34.CrossRefPubMed Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–34.CrossRefPubMed
9.
Zurück zum Zitat Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–43.CrossRefPubMed Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–43.CrossRefPubMed
10.
Zurück zum Zitat Wilffert B, Swen J, Mulder H, Touw D, Maitland-Vander Zee AH, Deneer V. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011;33(1):3–9.CrossRefPubMed Wilffert B, Swen J, Mulder H, Touw D, Maitland-Vander Zee AH, Deneer V. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011;33(1):3–9.CrossRefPubMed
Metadaten
Titel
Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?
verfasst von
Ho Choi
JiHyeon Ryu
Heenam Seo
MinKu Kang
Eunyoung Kim
Publikationsdatum
01.10.2015
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2015
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0118-z

Weitere Artikel der Ausgabe 5/2015

International Journal of Clinical Pharmacy 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.